March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical study results about its PVAD IQ at the 2026 Technology and Heart Failure Therapeutics (THT) Conference in Boston.

March 3, 2026 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for treating cardiovascular and pulmonary diseases, recently reported late breaking echocardiography results from its Phase III clinical trial for ischemic heart failure of reduced ejection fraction (HFrEF), which affects millions of patients in the United States.   

March 3, 2026 — MedDream will present its cloud-native, AI-ready universal DICOM viewer in the Amazon Web Services (AWS) in-booth theater at HIMSS 2026 in Las Vegas.

Feb. 27, 2026 — The U.S. Food and Drug Administration (FDA) has approved Abbott’s CardioMEMS Hero device — a pulmonary artery (PA) pressure reader — to support the care of people living with heart failure. The reader contains new design features to help empower heart failure patients and their clinicians with the daily insights they need to detect and combat heart failure progression. Abbott will soon begin commercial release of the CardioMEMS Hero reader in the United States.

Feb. 25, 2026 — Gentuity LLC, a medical technology company specializing in next-generation intravascular imaging devices, has announced a commercial collaboration with GE HealthCare to further improve the availability of Gentuity's HF-OCT Imaging System and Vis-Rx PRIME Micro-Imaging Catheter. As part of the collaboration, GE HealthCare will help expand Gentuity's reach by connecting cardiac catheterization lab customers in the United States with Gentuity products.

Feb. 26, 2026 — Eko Health has partnered with Wayne General Hospital in Wayne County, Mississippi, to deploy SENSORA, an AI-assisted cardiac detection platform, across the hospital's emergency and primary care departments. The deployment integrates FDA-cleared artificial intelligence directly into frontline clinical workflows, supporting earlier identification of potential structural heart disease, low ejection fraction, and atrial fibrillation during both acute and routine examinations.

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the latest computer-assisted detection (CADe) radiography solution from Qure.ai. It powers the early identification, highlighting and categorizing of key positive findings on plain film chest X-rays to support emergency room (ER) physicians, family medicine practitioners and radiologists.

Feb. 10, 2026 – AccurKardia, a provider of ECG-based diagnostics technology, recently announced results from a new study demonstrating that its AI-enabled ECG technology, AK-AVS, can detect aortic stenosis years before patients require valve replacement and improve prediction of clinical outcomes.

Feb. 19, 2026 — Preliminary results from an Italian registry describe the risk profile of women experiencing acute coronary syndromes and provide insights to improve management.1 These findings were presented at the EAPCI Summit 2026, a new event organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), an association of the European Society of Cardiology (ESC).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now